House Energy and Commerce Committee ranking member Frank Pallone asks the Government Accountability Office to analyze how FDA paid for its reductions-in-force and whether user fee funds were used legally.
A group of academic and public health experts urges FDA to embrace greater transparency, scientific independence and regulatory consistency, arguing that public confidence in the agency has eroded amid concerns over political interference and shifting regulatory standards.
House Energy and Commerce Committee ranking member Frank Pallone asks the Government Accountability Office to analyze how FDA paid for its reductions-in-force and whether user fee funds were used legally.
A group of academic and public health experts urges FDA to embrace greater transparency, scientific independence and regulatory consistency, arguing that public confidence in the agency has eroded amid concerns over political interference and shifting regulatory standards.
FDA warns South El Monte, CA-based International Medication Systems about CGMP violations in its production of finished drugs.
Biogen executives attempt to reassure investors Tuesday that its experimental anti-tau Alzheimer's disease therapy remains a promising late-stage candidate despite a sharp market selloff following detailed Phase 2 study results that raised questions about the drug's dose-response profile.
